Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iscalimab in moderate to severe myasthenia gravis
NCT02565576Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2015
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of iscalimab in myasthenia gravis (MG), sponsored by Novartis. Started Sep 2015; status: completed.
02
Drugs
iscalimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT02565576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02565576.